Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Using index funds for stock diversification can simplify your investment strategy. Explore how they can provide broad market exposure.
23,126 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Nike's profit margins fell as the company faced pricing, demand, and currency headwinds. This guide breaks down the m...
The AI boom isn’t a one-stock story. Here are three well-positioned names beyond Nvidia that could fuel the next rall...
Adobe prepares to report Q2 results after the bell as investors scrutinize AI-driven growth, ARR expansion, and capit...
Micron Technology has powered higher this year on AI demand, delivering a staggering rally. Yet veteran traders urge ...
Micron insiders are unloading stock at a pace not seen since 2010, even as MU rockets on AI memory demand. This piece...
Novo Nordisk signals a major Wegovy price cut set for January 2027, triggering a sharp market reaction as the stock s...
Jim Cramer’s take on Power Solutions International’s sharp drop spotlights a potential entry point for data center-re...
Citi has joined a growing chorus of concerns around Super Micro Computer, trimming its price target to $25 amid expor...
GameStop’s bid to acquire eBay is stirring a heated market debate over value and risk. Analysts say the move may be m...
Geopolitical shocks often rattle heavy machinery stocks like Caterpillar. This guide breaks down the buy, sell, or ho...
As RH prepares for the (rh) 2026 earnings call, investors want clarity on growth, margins, and strategy. This article...